Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment

Leong Lee, Ross Campbell, Michaela Scheuermann-Freestone, Rachel Taylor, Prasad Gunaruwan, Lynne Williams, Houman Ashrafian, John Horowitz, Alan G Fraser, Kieran Clarke, Michael Frenneaux

Research output: Contribution to journalArticlepeer-review

311 Citations (Scopus)


Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients.
Original languageEnglish
Pages (from-to)3280-8
Number of pages9
Issue number21
Publication statusPublished - 22 Nov 2005


  • Aged
  • Cardiovascular Agents
  • Chronic Disease
  • Echocardiography, Stress
  • Fatty Acids
  • Female
  • Glucose
  • Heart Failure
  • Humans
  • Male
  • Middle Aged
  • Myocardial Ischemia
  • Myocardium
  • Oxygen Consumption
  • Perhexiline
  • Quality of Life
  • Stroke Volume
  • Treatment Outcome

Cite this